Japanese growth for Boehringer Ingelheim as Pradaxa filing nears
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is planning to apply for the Japanese approval of Pradaxa (dabigatran) for stroke prevention in atrial fibrillation patients in the first quarter of next year, only months after the scheduled submissions in other key markets.